hydroxychloroquine has been researched along with valganciclovir in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Blanco, J; Buzón, MJ; Carrillo, J; Clotet, B; Martínez-Picado, J; Massanella, M; Negredo, E; Pérez-Álvarez, N; Puertas, MC; Puig, J | 1 |
1 review(s) available for hydroxychloroquine and valganciclovir
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
1 trial(s) available for hydroxychloroquine and valganciclovir
| Article | Year |
|---|---|
Raltegravir intensification shows differing effects on CD8 and CD4 T cells in HIV-infected HAART-suppressed individuals with poor CD4 T-cell recovery.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Female; Flow Cytometry; Ganciclovir; HIV Infections; Humans; Hydroxychloroquine; Inflammation; Lymphocyte Activation; Male; Middle Aged; Prospective Studies; Pyrrolidinones; Raltegravir Potassium; Valganciclovir; Viral Load | 2012 |